Azitra is trading at $1.42, down 5.96% in after-hours trading; available reporting does not identify a specific cause for the decline.
- On October 26, Azitra announced positive ex vivo results for cosmetic candidate ATR-COSF, reporting reduced wrinkle appearance and improved skin-elasticity measures in human skin samples.
- Initial results from a planned first-in-human study are expected by year-end.
- The announcement was linked to a sharp rise during regular trading. The broader market rose, but does not clearly explain the after-hours decline.